Fieldpoint Private Securities LLC Takes $147,000 Position in Eli Lilly and Co (LLY)
Fieldpoint Private Securities LLC acquired a new position in shares of Eli Lilly and Co (NYSE:LLY) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,713 shares of the company’s stock, valued at approximately $147,000.
Several other institutional investors also recently made changes to their positions in LLY. Kovitz Investment Group Partners LLC raised its stake in shares of Eli Lilly and by 2.1% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 7,450 shares of the company’s stock worth $627,000 after purchasing an additional 151 shares in the last quarter. OLD Mutual Customised Solutions Proprietary Ltd. raised its stake in shares of Eli Lilly and by 18.2% during the 1st quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 15,482 shares of the company’s stock worth $1,302,000 after purchasing an additional 2,382 shares in the last quarter. First Financial Equity Corporation bought a new stake in shares of Eli Lilly and during the 1st quarter worth approximately $252,000. Janus Capital Management LLC raised its stake in shares of Eli Lilly and by 2.8% during the 1st quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock worth $733,731,000 after purchasing an additional 237,619 shares in the last quarter. Finally, Salem Investment Counselors Inc. raised its stake in shares of Eli Lilly and by 23.3% during the 1st quarter. Salem Investment Counselors Inc. now owns 35,800 shares of the company’s stock worth $3,015,000 after purchasing an additional 6,754 shares in the last quarter. Institutional investors own 76.30% of the company’s stock.
A number of research firms recently weighed in on LLY. BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, October 24th. Barclays boosted their target price on Eli Lilly and from $90.00 to $98.00 and gave the stock an “overweight” rating in a report on Friday, October 13th. Berenberg Bank reissued a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a report on Thursday, October 26th. Zacks Investment Research lowered Eli Lilly and from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Cowen reissued a “buy” rating and set a $95.00 target price on shares of Eli Lilly and in a report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company’s stock. Eli Lilly and currently has a consensus rating of “Hold” and an average price target of $92.14.
Eli Lilly and Co (NYSE:LLY) opened at $86.57 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and Co has a 1-year low of $74.00 and a 1-year high of $89.09. The company has a market capitalization of $95,320.00, a price-to-earnings ratio of 41.22, a price-to-earnings-growth ratio of 1.60 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same period in the prior year, the firm posted $0.88 EPS. The company’s revenue for the quarter was up 9.0% on a year-over-year basis. equities research analysts predict that Eli Lilly and Co will post 4.22 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be issued a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a yield of 2.60%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is currently 99.05%.
In other Eli Lilly and news, SVP Jeffrey N. Simmons sold 12,500 shares of the company’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $86.46, for a total value of $1,080,750.00. Following the transaction, the senior vice president now directly owns 124,522 shares of the company’s stock, valued at approximately $10,766,172.12. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the transaction, the insider now directly owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 251,088 shares of company stock worth $22,041,236. Insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.